본문으로 건너뛰기
← 뒤로

Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China.

코호트 1/5 보강
Frontiers in pharmacology 📖 저널 OA 100% 2021: 3/3 OA 2022: 12/12 OA 2023: 4/4 OA 2024: 24/24 OA 2025: 185/185 OA 2026: 100/100 OA 2021~2026 2026 Vol.17() p. 1745000 OA
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
107 patients diagnosed with early-stage FL between 2000 and 2020 at the National Cancer Center in China.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No treatment modality showed a clear survival advantage in this limited-size cohort, while relapse was uncommon and more frequently locoregional than systemic. POD24 identified a small subset of patients with inferior survival, highlighting the need for individualized, risk-adapted management and long-term follow-up.

Xu C, Yang S, Liu Y, Wu Y, Liu X, Zhong QZ, Yang Y, Wu T, Chen SY, Chen B, Song YW, Fang H, Jin J, Liu YP, Jing H, Tang Y, Li N, Lu NN, Zhang WW, Wang SL, Zhu J, Qi SN, Li YX

📝 환자 설명용 한 줄

[BACKGROUND AND PURPOSE] The optimal management of early-stage follicular lymphoma (FL) remains an active research area, particularly in China.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 107
  • 추적기간 86 months
  • 연구 설계 cohort study

이 논문을 인용하기

↓ .bib ↓ .ris
APA Xu C, Yang S, et al. (2026). Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China.. Frontiers in pharmacology, 17, 1745000. https://doi.org/10.3389/fphar.2026.1745000
MLA Xu C, et al.. "Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China.." Frontiers in pharmacology, vol. 17, 2026, pp. 1745000.
PMID 41613778 ↗

Abstract

[BACKGROUND AND PURPOSE] The optimal management of early-stage follicular lymphoma (FL) remains an active research area, particularly in China. This retrospective cohort study examined long-term survival outcomes, recurrence patterns, and potential prognostic factors in patients with early-stage FL.

[MATERIALS AND METHODS] We retrospectively analyzed 107 patients diagnosed with early-stage FL between 2000 and 2020 at the National Cancer Center in China. Treatment modalities included radiotherapy with or without chemoimmunotherapy or chemotherapy, chemoimmunotherapy or chemotherapy, and observation. Overall survival, progression-free survival, and lymphoma-specific survival were assessed using the Kaplan-Meier method and Cox regression models. We evaluated failure patterns, including locoregional and systemic failures, using cumulative incidence analysis with competing risks. Exploratory LASSO regression and machine learning-based approaches were applied to identify potential prognostic factors.

[RESULTS] The median age was 53 years, and the median follow-up was 86 months. In this 20-year real-world cohort from the National Cancer Center of China (n = 107), long-term outcomes were favorable, with 5- and 10-year rates of 88.7% and 68.8% for OS, 93.3% and 89.9% for LSS, and 76.0% and 57.2% for PFS. No statistically significant differences in survival or cumulative failure were observed across initial management strategies, including radiotherapy with or without systemic therapy, systemic therapy alone, and observation. Recurrence occurred in 21 patients (19.6%), predominantly locoregional (14 locoregional only vs. 6 systemic only; 1 both). The 5- and 10-year cumulative incidences were 16.3% and 19.5% for overall failure, 14.5% and 16.2% for locoregional failure, and 3.1% and 4.8% for systemic failure. POD24 occurred in 6.5% of patients and was associated with inferior OS, although event numbers were limited. Low neutrophil-to-lymphocyte ratio (NLR <1.8) was associated with poorer survival in exploratory analyses.

[CONCLUSION] Patients with early-stage FL in this 20-year real-world Chinese cohort demonstrated an overall favorable long-term prognosis across diverse initial management strategies. No treatment modality showed a clear survival advantage in this limited-size cohort, while relapse was uncommon and more frequently locoregional than systemic. POD24 identified a small subset of patients with inferior survival, highlighting the need for individualized, risk-adapted management and long-term follow-up.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기